MedTrace Logo

Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis

NCT03765450 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2025-05-16

No results posted yet for this study

Summary

This is an open-label, prospective, observational study with the primary objective to characterize the pharmacokinetics of infliximab in patients with Acute Severe Ulcerative Colitis.

Conditions

Interventions

DRUG

Infliximab

Patients will receive infliximab at the discretion of their physician as part of standard of care.

Sponsors & Collaborators

  • Alimentiv Inc.

    lead OTHER

Principal Investigators

  • Niels Vande Casteele · UCSD

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-21
Primary Completion
2023-12-22
Completion
2026-03-02

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03765450 on ClinicalTrials.gov